Boehringer Ingelheim International GmbH - Company Profile
Powered by
All the data and insights you need on Boehringer Ingelheim International GmbH in one report.
- Save hours of research time and resources with
our up-to-date Boehringer Ingelheim International GmbH Strategy Report
- Understand Boehringer Ingelheim International GmbH position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.
Boehringer Ingelheim International GmbH premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Human Pharmaceuticals: | Contract Manufacturing | Spiriva |
Prescription Medicine | Inspiolto Respimat | |
Cardiometabolic Diseases | Striverdi Respimat | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In January, the company entered into an agreement with Suzhou Ribo Life Sciences Co Ltd to create novel medicines for those suffering from liver problems. |
2023 | Acquisitions/Mergers/Takeovers | In November, the company announced the acquisition of T3 Pharmaceuticals AG. |
2023 | Contracts/Agreements | In November, the company entered into a partnership with IBM to explore innovative candidate antibodies for the advancement of effective therapeutics. |
Competitor Comparison
Key Parameters | Boehringer Ingelheim International GmbH | F. Hoffmann-La Roche Ltd | Pfizer Inc | AbbVie Inc | Novartis AG |
---|---|---|---|---|---|
Headquarters | Germany | Switzerland | United States of America | United States of America | Switzerland |
City | Ingelheim am Rhein | Basel | New York | North Chicago | Basel |
State/Province | Rheinland-Pfalz | - | New York | Illinois | - |
No. of Employees | 53,000 | 103,605 | 88,000 | 50,000 | 76,057 |
Entity Type | Private | Public | Public | Public | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Hubertus von Baumbach | Chairman | Executive Board | - | - |
Paola Casarosa | Managing Director - Innovation Unit | Senior Management | 2023 | 49 |
Gagandeep Singh | Head - Human Pharma India; Managing Director | Senior Management | 2023 | - |
Shashank Deshpande | Managing Director - Animal Health Business | Senior Management | 2023 | 50 |
Frank Hubler | Head - Corporate Finance, Accounting, Controlling and Tax | Senior Management | 2019 | 53 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer